超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Foundation Medicine 
美國Foundation Medicine

Cancer care is undergoing a transformation towards personalized treatment. Foundation Medicine, launched by leaders in cancer genomics, cancer biology, clinical oncology and information sciences, is dedicated to helping bring this transformation into routine clinical practice. Harnessing next-generation sequencing and other advanced technologies, Foundation is developing clinical laboratory tests that will broadly capture the relevant tumor genomic and other molecular information in an individual patient’s disease, and connect it with a knowledgebase of relevant clinical data to help their oncologist determine the right treatment – truly enabling personalized cancer medicine.

The past decade of cancer research has seen an expansion of available targeted therapies and a detailed molecular mapping of thousands of tumors at cancer genome centers worldwide. It is now becoming technically possible to comprehensively characterize the molecular drivers of cancer in an individual patient. This information, coupled with the growing availability of targeted therapies, could lead to better outcomes for some patients and more efficient allocation of resources in healthcare delivery and drug development.

Foundation Medicine’s team has the unique knowhow to translate the promise of these advances into everyday clinical care, starting with comprehensive tests that work with routine specimens, reliably meet clinical standards of sensitivity and specificity across hundreds of gene sequences, have rapid turn-around times, and help the clinician extract actionable insights from the resulting analysis by presenting it in the context of relevant clinical data. .

Foundation was launched by leaders from the Broad Institute, the Dana Farber Cancer Institute, Harvard Medical School and the Massachusetts Institute of Technology. It is backed by Third Rock Ventures, bringing the scientific and medical expertise of its founding academic advisors together with experienced company-building and industry leadership in the areas of biotechnology and molecular diagnostics.